Security key
92765F108
Viracta Therapeutics, Inc. - Common Stock (VIRX)
CUSIP: 92765F108
Q4 2024 13F Holders as of 31 Dec 2024
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 3,616,059
- Total 13F value
- $582,967
- Share change
- -1,964,045
- SEC-reported price per share
- $0.16
- Number of holders
- 31
- Value change
- -$433,109
- Number of buys
- 10
- Number of sells
- 14
- Shares outstanding
- 19,711,628
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q4 2024
Institutions
31
Top holders
10
VIRX full security history
Ownership snapshot
Full 13F holder table
Viracta Therapeutics, Inc. SEC filings
Viracta Therapeutics, Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of VIRX - Viracta Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
FORWARD VENTURES V LP
Disclosed value leader
CITADEL ADVISORS LLC
Comparable rows
15/15
Latest evidence
31 Dec 2024
13D/G
13F
Lead comparable stake: 4.3%
13D/G row: FORWARD VENTURES V LP
Showing 1-6 of 15 holder rows.
Quick read
FORWARD VENTURES V LP leads the comparable SEC ownership view at 4.3%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens FORWARD VENTURES V LP's linked filing trail.
Comparable ownership
Top 5
FORWARD VENTURES V LP
4.3%
CITADEL ADVISORS LLC
7.7%
VANGUARD GROUP INC
4.8%
Samsara BioCapital, LLC
3.5%
Stonepine Capital Management, LLC
2.5%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| FORWARD VENTURES V LP |
13D/G
|
4.3%
|
$16,952
847,600 shares
|
$0 | 31 Dec 2024 |
| CITADEL ADVISORS LLC |
13F
Company
|
7.7%
|
$351,784
1,520,240 shares
|
— | 30 Sep 2024 |
| VANGUARD GROUP INC |
13F
Company
|
4.8%
|
$220,486
954,485 shares
|
— | 30 Sep 2024 |
| Samsara BioCapital, LLC |
13F
Company
|
3.5%
|
$159,599
689,709 shares
|
— | 30 Sep 2024 |
| Stonepine Capital Management, LLC |
13F
Company
|
2.5%
|
$115,700
500,000 shares
|
— | 30 Sep 2024 |
| Laurion Capital Management LP |
13F
Company
|
1.7%
|
$76,869
332,189 shares
|
— | 30 Sep 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
31
Shares
3,616,059
Rows available
31
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2024 vs Q3 2024 Across Filers
Q3 2024 holders
37
Q4 2024 holders
31
Holder diff
-6
| Investor | Q3 2024 Shares | Q4 2024 Shares | Share Diff | Share Chg % | Q3 2024 value | Q4 2024 value | Value change | Value Chg % |
|---|